Cannabis Stocks

Loss-Making Tilray, Inc. (NASDAQ:TLRY) Expected To Breakeven

Tilray, Inc.'s (NASDAQ:TLRY): Tilray, Inc. engages in the research, cultivation, processing, and distribution of...

• 
  Spectral Medical Inc. (TSE:EDT) Is Expected To Breakeven

  Simply Wall St.
• 
  Flexion Therapeutics, Inc. (NASDAQ:FLXN): When Will It Breakeven?

  Simply Wall St.

Scotts Miracle-Gro Up 33% in 3 Months: What's Driving It?

Upbeat views and bright prospects in the Hawthorne business are driving Scotts Miracle-Gro's (SMG) shares.

4 Reasons to Own AbbVie Stock as Coronavirus Woes Linger

AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are off to a strong start.

These 3 Value Stocks Are Absurdly Cheap Right Now

These companies have low P/E ratios and high dividend yields and investors stand to profit from that combination.

• 
  Are Investors Undervaluing The Gym Group plc (LON:GYM) By 49%?

  Simply Wall St.
• 
  Is NVR Stock a Solid Choice Right Now?

  Zacks

Are Options Traders Betting on a Big Move in Tilray (TLRY) Stock?

Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.

• 
  Is the Options Market Predicting a Spike in PBF Energy (PBF) Stock?

  Zacks
• 
  Is the Options Market Predicting a Spike in McEwen Mining (MUX) Stock?

  Zacks

5 Popular Stocks I Wouldn't Buy With Free Money

Uncertainty and panic related to the coronavirus disease 2019 (COVID-19) pandemic completely pulled the rug out from beneath the stock market and ultimately sent the benchmark S&P 500 lower by 34% in a mere 33 days. The recently ended quarter featured the best returns for the broad-market indexes since 1998, with the technology-focused Nasdaq Composite galloping to new all-time highs. Right now, there are five exceptionally popular stocks that investors can't seem to get enough of lately that, frankly, I wouldn't buy with free money.

Get Ready for a Green Rush in the Second Half: 3 Must Buys

With more states in the US and Canada likely to legalize marijuana and calls for marijuana decriminalization growing louder, the cannabis industry is poised to bounce back in the second half.

Better Cannabis Stock: Aphria vs. Canopy Growth

Today, I'll look at two of the top pot stocks in the industry -- Aphria (NASDAQ: APHA) and Canopy Growth (NYSE: CGC) -- and assess which of these leading cannabis producers is the better stock to hold in your portfolio. One of the ways Aphria has established itself as one of the safer stocks in the industry is by being able to stay in the black on a relatively consistent basis. In its most recent quarterly results, which the company released on April 14, Aphria posted a net income of 5.7 million Canadian dollars on net revenue of CA$144.4 million.

Got $5,000? Buy These 3 High-Yield Dividend Stocks That Are Money Machines

You can do just that with dividend stocks. Others are on such shaky ground that their dividends are in jeopardy. If you've got $5,000 to invest, here are three high-yield dividend stocks that are flat-out money machines.

• 
  Here's What Brookfield Infrastructure Corporation's (NYSE:BIPC) Shareholder Ownership Structure Looks Like

  Simply Wall St.
• 
  3 Top Dividend Stocks to Buy in July

  Motley Fool

Aurora Cannabis Appoints International Consumer Packaged Goods Executive Miguel Martin as Chief Commercial Officer

Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that Miguel Martin, President of Aurora USA and head of Reliva, LLC ("Reliva"), has been appointed Chief Commercial Officer of Aurora, effective immediately. Mr. Martin will replace Darren Karasiuk who has held this position at Aurora since February 2019.

• 
  Camera Catches Stunning Daytime Aurora In The Sky

  geobeats
• 
  Aurora opening 3 rec centers today

  7News - The Denver Channel

Corbus Pharmaceuticals Holdings Inc (CRBP): Are Hedge Funds Right About This Stock?

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

• 
  Were Hedge Funds Right About Dumping Star Bulk Carriers Corp. (SBLK)?

  Insider Monkey
• 
  Hedge Funds Are Selling Western Midstream Partners, LP (WES)

  Insider Monkey

Can Cannabis 2.0 Products Boost Canopy Growth and Organigram in 2020?

Will the potential of cannabis derivatives products push these two cannabis companies towards growth this year?

Why Altria Stock Lost 21% in the First Half of 2020

Shares of Altria Group (NYSE: MO) have gone up in smoke this year as the domestic Marlboro maker fell early in the year after it took another impairment on its Juul Labs stake and then got slammed by the coronavirus pandemic. According to data from S&P Global Market Intelligence, the stock has slipped 21% through the first six months of the year. Altria began the year with Juul facing stiff headwinds as regulators sought to ban flavored e-cigarette pods, the latest setback for the once-promising cigarette disruptor, with the e-cigarette brand embroiled in a number of lawsuits at the state level.

AbbVie (ABBV) Hits Fresh High: Is There Still Room to Run?

AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

• 
  5 High-Yield Dividend Stocks to Watch

  Motley Fool
• 
  AbbVie Is Cheap and Pays an Attractive Yield

  InvestorPlace

Better Coronavirus Stock: Eli Lilly or AbbVie?

Eli Lilly (NYSE: LLY) is a veteran in the pharmaceutical community and has been in business for over 140 years. AbbVie (NYSE: ABBV) is a relative newcomer and was established back in 2013 after spinning off parent organization Abbott Laboratories. Last year was a good one for Eli Lilly.

• 
  Better Buy: Eli Lilly vs. Johnson & Johnson

  Motley Fool
• 
  2 Top Diabetes Stocks to Buy Right Now

  Motley Fool

5 High-Yield Dividend Stocks to Watch

One of the places they've found cash returns is in dividend stocks, particularly those that offer a relatively high payout. Fortunately, some high-yield dividend stocks remain well-positioned to sustain their dividends. AbbVie (NYSE: ABBV) spent most of its history as a subsidiary of Abbott Laboratories before becoming an independent company in 2013.

57% of Americans plan to attend or host a 4th of July BBQ as new coronavirus cases hit daily record

Americans still plan to attend or host a cookout this 4th of July weekend as the U.S. reported a record-setting 53,000 new coronavirus cases.

This Cannabis Stock Trend May Hold Clues to the Industry's Future

There's been some significant buyer's remorse of late in the cannabis industry, with would-be acquirers backing out of deals or amending them. It's not uncommon for such deals to change between the time they're proposed and the day they close, but the frequency at which that's happening in the cannabis industry is raising eyebrows among investors. On June 25, Canopy Growth (NYSE: CGC) and Acreage Holdings (OTC: ACRGF) agreed to change the terms of their deal.

• 
  Can Cannabis 2.0 Products Boost Canopy Growth and Organigram in 2020?

  Motley Fool
• 
  3 Reasons to Buy Canopy Growth Instead of Aurora Cannabis

  Motley Fool

Facebook Under Fire as Companies Pause Social Media Ads: List

(Bloomberg) -- Here’s a list of companies that are planning to halt spending on social media. Some have joined a boycott of Facebook Inc. after critics accused the social network of inadequately policing hateful and misleading content on its platform:Harley Davidson Inc. -- The motorcycle maker said in an email it was pausing Facebook ads in July “to stand in support of efforts to stop the spread of hateful content.”Pernod Ricard SA -- The French distiller of Jameson whiskey and Absolut Vodka, which spends more than 1.5 billion euros ($1.69 billion) on advertising annually, is boycotting Facebook and some other U.S. sites through July 31 and working with partners on an app to help victims of online abuse.Daimler AG -- The Mercedes-Benz maker is pausing its paid advertising on Facebook platforms in July, while adding that it expects to the relationship to resume because it’s confident the social-media company will take “necessary steps.”Molson Coors Beverage Co. -- The brewer is choosing to pause advertising on Facebook, Instagram and Twitter while it reviews its own standards and ways to protect the brands and guard against hate speech, Chief Marketing Officer Michelle St. Jacques said in an internal email.Constellation Brands -- The maker of Corona beer and Kim Crawford wines is pausing Facebook ads for the month of July.Dunkin’ Brands Group -- The donut chain is temporarily pausing its paid media on Facebook and Instagram, a spokesperson says, adding that it’s in discussions with Facebook about efforts to stop hate speech and thwart “the spread of “racist rhetoric and false information.”Lego A/S -- Stopping all advertising on social media for at least 30 days to review its standards and will “invest in other channels” during that time.The Body Shop -- The beauty chain says it’s halting paid activity on all Facebook channels and asking the social-media company to enhance and enforce its content-moderation policies.Starbucks Corp. -- Pausing advertising on all social media platforms. Will post on social media without paid promotion.Microsoft Corp. -- Paused global advertising spending on Facebook and Instagram because of concerns about ads appearing next to inappropriate content, according to a person familiar with the matter.Unilever Plc -- Halting advertising on Facebook, Instagram and Twitter in the U.S. through Dec. 31.Volkswagen AG -- The ad stop on Facebook affects the direct ad accounts of the German manufacturer’s brands, including Porsche, Audi and Lamborghini. VW, its ad agencies and the Anti Defamation League will enter talks with Facebook over how to deal with hate speech, discrimination and false information, according to an emailed statement.Mars -- Starting in July, a pause on paid advertising globally across social-media platforms, including Facebook, Instagram, Twitter and Snapchat.Target Corp. -- Pausing ads on Facebook in July.Coca-Cola Co. -- Pausing advertising on all social media platforms.Clorox Co. -- Will stop advertising spending with Facebook through December.Conagra Brands Inc. -- Will stop advertising in U.S. on Facebook and Instagram through the rest of the year.Ford Motor Co. -- Halting U.S. social media for 30 days, won’t purchase social media ads for Bronco unveiling.Honda Motor Co. -- “For the month of July, Honda will withhold its advertising on Facebook and Instagram, choosing to stand with people united against hate and racism.” Acura, a Honda brand, said in a tweet that it was “choosing to stand with people united against hate and racism.”Hershey Co. -- Will halt spending on Facebook in July and cut its spend on the platform by a third for the remainder of the year, according to Business Insider.Diageo Plc -- Pausing paid advertising globally on major social media platforms beginning in July.PepsiCo Inc. -- Pulling ads on Facebook from July through August.Verizon Communications Inc. -- “We’re pausing our advertising until Facebook can create an acceptable solution that makes us comfortable and is consistent with we’ve done with YouTube and other partners,” said John Nitti, chief media officer for Verizon.SAP SE -- “We will suspend all paid advertisements across Facebook and Instagram until the company signals a significant, action-driven commitment to combatting the spread of hate speech and racism on its platforms.”Levi Strauss & Co. -- Pausing all paid Facebook and Instagram advertising globally and across all brands through July.Diamond Foundry Inc. -- Pulling all of advertising from Facebook, including Instagram, for the month of July.Patagonia Inc. -- Will pull all ads on Facebook and Instagram, effective immediately, through at least the end of July, pending meaningful action from Facebook.Viber Media Inc. -- The messaging service, owned by Japanese conglomerate Rakuten, plans to cut ties with the social network entirely, according to the Guardian.VF Corp. -- The North Face will pause ads on Facebook for the month of July. Vans, another VF brand, will also pull ad dollars from Facebook and Instagram next month, and said it will use the money to support Black communities through empowerment and education programs.REI -- “For 82 years, we have put people over profits. We’re pulling all Facebook/Instagram advertising for the month of July.”Upwork Inc. -- No Facebook advertising in July.Eileen Fisher Inc. -- Pulling ads from Facebook through July.Adidas AG -- Will stop ads on Facebook and Instagram internationally through July, according to Adweek.Puma SE -- Will stop all advertisements on Facebook and Instagram throughout July.Madewell Inc. -- Will pause ads on Facebook and Instagram through July.Pfizer Inc. -- Removing all advertising from Facebook and Instagram in July, calls on Facebook to heed the concerns of the StopHateForProfit boycott campaign “and take action.”Chipotle Mexican Grill Inc. -- To pause Facebook advertising beginning July 1, according to an email.Chobani -- The Greek-yogurt company paused all paid social-media advertising.Peet’s Coffee -- Paused advertising on Facebook.Sony Interactive Entertainment Inc. -- ”In support of the StopHateForProfit campaign, we have globally suspended our Facebook and Instagram activity, including advertising and non-paid content, until the end of July.”(Updates with Sony Interactive Entertainment)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

• 
  Facebook Tells Advertisers There’s No Perfect ‘Fix’ for Hate Speech

  WWD
• 
  The Facebook ad boycott could pay off for companies more than advertising on Facebook

  MarketWatch

Were Hedge Funds Right About Piling Into AbbVie Inc (ABBV)?

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. We are almost done with the second quarter. Investors decided […]

• 
  Hedge Funds Are Selling Dr. Reddy’s Laboratories Limited (RDY)

  Insider Monkey
• 
  Hedge Funds Done Buying Netfin Acquisition Corp. (NFIN)?

  Insider Monkey

AbbVie Is Cheap and Pays an Attractive Yield

AbbVie (NYSE:ABBV) stock is both cheap and has a very attractive dividend yield. In addition, this pharmaceutical company's growth prospects are high, now that its purchase of Allergan is closed.Source: Piotr Swat / Shutterstock.com For example, the stock trades on a forward earnings ratio of just 9.2 times 2020 expected earnings. It is even lower with 2021 earnings prospects.In addition, the $4.72 per share annual dividend is very attractive to most investors for several reasons. For one, the dividend yield for ABBV stock is much higher than the average stock.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSecondly, the dividend is likely to keep on growing at a nice pace. For example, on June 17 AbbVie declared a $1.18 quarterly dividend for the third time. After the fourth quarterly dividend at this rate, I suspect the company will raise the dividend in Q4. According to Seeking Alpha, AbbVie has had a 20.86% dividend growth rate annually on a compounded basis. * 7 Utilities Stocks to Buy With Reassuring DividendsLastly, the dividend is still well covered by the company's earnings. For example, Seeking Alpha's poll of 15 analysts' estimates of 2020 is $10.46 per share. But the dividend rate right now is $4.72. So the dividend is more than 100% covered by earnings. Why Is AbbVie Stock So Cheap?AbbVie's main revenue driver, up until its recent acquisition of Allergan, was Humira, a rheumatoid arthritis drug. It also acts as an anti-inflammatory drug for other conditions including Crohn's disease, psoriasis, ulcerative colitis, etc. It is the world's best-selling drug.But adalimubab, the actual name of the drug, went off-patent in 2016. Recently, generic versions of the drug have become available.The problem for AbbVie is that up until Q1 2020, Humira accounted for 54.5% of its revenue. AbbVie said its Q1 sales were $8.619 billion, up 10.7% year-over-year. But Humira sales were $4.703 billion, up 6.4%.This is the most likely reason for AbbVie's low valuation. It is too reliant on one drug and that drug is now off-patent. The market assumes that generic drugs will eventually overtake that revenue stream for AbbVie. But things are not as bad as that. Why Investors Need Not Be So WorriedFirst of all, Humira does not go completely off-patent in the U.S., even though in some other countries this has happened. Its core U.S. patents went off-patent in 2016, but it has a "patent thicket" that extends its exclusivity to as late as 2034, according to one source. Another source says its exclusivity extends to 2023.Second, the company will now have a much lower reliance on Humira. On May 8, AbbVie closed on its acquisition of Allergan for about $63 billion in cash and stock. Allergan made $3.6 billion in sales in its latest quarter and $378 million in profits.So you can see that on a pro-forma combined basis, Humira will now account for a lower amount of total sales. They would total $12.2 billion on a combined basis in Q1. But Humira's $4.7 billion would account for only 38.4%. Given that other drugs in the portfolio are likely growing faster than Humira, that portion will continue to fall.So the risk is falling for the over-reliance on one drug. But some analysts point out that AbbVie's other drugs and its pipeline are very attractive as growth drivers. Valuing AbbVie StockGiven that management clearly seems intent on growing its dividend, we can use this aspect of the return of capital to value AbbVie stock. Let's assume the dividend next rises 10% next year, just like it did this year. That would put the annual dividend at $5.20 per share.The historical dividend yield for AbbVie stock has been 4.22% over the past four years, according to Seeking Alpha. Therefore, by taking the $5.20 dividend per share and dividing it by 4.22%, the target price is $123.22 per shareThat represents a significant gain over the current price of about $98. So not only is AbbVie stock cheap with an attractive dividend yield, but it also has good upside potential.Mark Hake runs the Total Yield Value Guide which you can review here. As of this writing, Mark Hake, CFA does not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post AbbVie Is Cheap and Pays an Attractive Yield appeared first on InvestorPlace.

• 
  Here's What Brookfield Infrastructure Corporation's (NYSE:BIPC) Shareholder Ownership Structure Looks Like

  Simply Wall St.
• 
  3 Top Dividend Stocks to Buy in July

  Motley Fool

Aurora Cannabis Inc. (ACB) Upgraded to Buy: Here's Why

Aurora Cannabis Inc. (ACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

• 
  Franco-Nevada Shares Up 32% YTD: What's Driving the Rally?

  Zacks
• 
  Qutoutiao (QTT) Catches Eye: Stock Jumps 12%

  Zacks